Neorecormon is a medicine containing the active ingredient(s) epoetin beta. On this page you will find out more about Neorecormon, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: epoetin beta
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Neorecormon 6000 units/0.3 mL injection, 6 x 0.3 mL syringes
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Indications as of 12 DECEMBER 2008. Neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (CKD) in patients on dialysis and symptomatic patients not yet undergoing dialysis. To increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. For the prevention of anaemia of prematurity in infants with a birth weight of 750g to 1500g and a gestational age of less than 34 weeks. For the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy.
Table of characteristics
|Visual appearance||1 mL ready to use syringe containing colourless, clear to slightly opalescent solution|
|Route of administration||Intravenous|
6: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store at 2 to 8 degrees Celsius|
|Storage conditions||Refrigerate,Protect from Light,Do not Freeze|
|Life time||2 Years|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 October 2017
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.